Naturally Pure Products Salvestrol Platinum (Salvacare)

Salvestrol® Description & Directions

Table of Contents

1. Directions for Use
2. Precautions & Storage
3. Ingredients & Free From
4. Frequently Asked Questions (FAQs)
5. About NESEMs™
6. Companion Products
7. Clinical Studies

Directions

Back to Contents

Precautions

• Consult a Professional: Consult your healthcare professional prior to use if pregnant or breastfeeding.
• Natural Variation: Colour may vary from batch to batch due to the natural plant extracts used.
• Safety: Keep out of reach of children.
• Dietary Notes: Dietary supplements should not be used as a substitute for a balanced diet and healthy lifestyle.

Storage

Store in a cool, dry place below 25°C.

Salvestrol® is a registered trademark licensed to Nature’s Defence Research Ltd.

Back to Contents

Ingredients

• Note: Contains NO grapefruit or extracts from grapefruit.
• Note: Contains extracts from Grape Seed, but not whole grapes.

Free From

No artificial flavours, colours, or preservatives. Capsule shell composed of hydroxypropylmethylcellulose.

Back to Contents

FAQs

1. Can I take Salvestrols with chemotherapy or radiation?

Salvestrols are plant-derived compounds with no reported side effects or known interactions with conventional treatments. A small study indicated that Salvestrols may improve quality of life and overall survival when used as an adjunct to standard cancer treatments.

2. Can I break open the capsules and take them as a powder?

Yes. However, the powder has a very bitter taste, so it is recommended to test a small amount first to ensure it is palatable for you.

3. Can I take other supplements between my two doses?

Yes. Specific cofactors that may increase effectiveness include Biotin, Vitamin B3, Vitamin B12, Vitamin C, Iron, and Magnesium. These are ideal to take between your Salvestrol doses.

4. I am using CBD or THC oils; can I use Salvestrols as well?

Yes. We suggest taking Salvestrols in the morning and your oils as far away as possible (e.g., late afternoon or evening) to avoid potential metabolic overlap.

5. Why should I take Salvestrols on an empty stomach?

This prevents Salvestrols from competing for absorption with other nutrients, giving them the best chance of being fully utilised by the body.

6. Why should I take two doses instead of one?

Salvestrols reach peak concentration roughly 3 hours after ingestion. A second dose boosts blood levels just as the first begins to diminish, lengthening the therapeutic window.

7. Why is exercise recommended 4 hours after the second dose?

Salvestrol metabolism is supported by an oxygen-rich environment. Engaging in a brisk walk or breathing exercises roughly 4 hours after your dose provides the oxygen necessary for optimal metabolism.

8. What do the “2000 points” mean?

This relates to the DNA-damaged cell selectivity of the proprietary blend. Regardless of the specific fruits on the label, each capsule is standardised to a potency of 2000 active Salvestrol points.

9. Why is 1000mg of Vitamin C recommended?

Ascorbic acid provides electron donation that supports the metabolism of Salvestrol by the CYP1B1 enzyme, helping it circulate longer and optimising its effectiveness.

10. If I forget a morning dose, can I take it in the evening?

While they can be metabolised at any time, morning is best as this is when CYP1B1 enzyme activity is at its highest.

Back to Contents

About NESEMs™ / NPP

Naturally Elicited, Specifically Extracted Molecules (NESMs) are compounds produced by plants as a natural defence mechanism. These are typically produced in response to environmental challenges, such as pathogens, in plants that have not been treated with pesticides.

Using a targeted supercritical fluid extraction approach, these specific molecules are isolated from the plant’s skin or pith to ensure maximum purity and potency.

Back to Contents

Best With (Companion Products)

• Biomax Vitamin C (Optimises metabolism)
• Moderaflam Capsules
• LypoSalve (For topical application)
• Great Lakes Collagen
• Essential Fatty Acids (Assists membrane transport)

Back to Contents

Clinical Studies & References

1. Salvestrols – Natural Products with Tumour Selective Activity.
2. Regulation, Function, and Tissue-Specific Expression of Cytochrome P450 CYP1B1.
3. Effect of NESEM™/S2013 in Indian Population as an Adjunct to Conventional Treatment.
4. Cancer and Related Case Studies Involving Salvestrol and CYP1B1.
5. Nutrition and Cancer: Further Case Studies Involving Salvestrol.
6. Salvestrols: A natural, targeted approach to preventing and treating cancer.
7. Natural Cancer Therapy Based on the Enzyme CYP1B1: A Commentary.
8. Cytochrome P450 1B1 overexpression in prostate cancer.
9. Immunohistochemical evaluation of CYP1B1 and p53 in breast cancer.

Back to Contents

Disclaimer

The content is not intended to be a substitute for professional advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition.

Salvestrol® Technical Information

Table of Contents

1. Key Clinical Points
2. Pharmacodynamics & Background
3. The NESEM® Advantage
4. Ingredients
5. Dosing Guide & Protocols
6. Optimising Effectiveness
7. Frequently Asked Questions (FAQs)
8. Full Clinical References

Key Clinical Points

• Deficiency Risks: Inadequate Salvestrol levels are associated with unregulated proliferation of abnormal cells.
• Natural Regulation: Salvestrols are utilised as part of the body’s innate cell cycle regulation process.
• Non-Cytotoxic: The effect is achieved through metabolic activation, not a direct cytotoxic response.
• High Selectivity: They demonstrate no effect on normal, healthy cells.
• Safe Integration: No known interactions; can be used alongside conventional treatments.
• Multifunctional: While not antioxidants, they exhibit anti-inflammatory and anti-fungal properties.

Back to Contents

Pharmacodynamics & Background

The Mechanism of Action

• Bypassing First-Pass: Salvestrols escape initial first-pass metabolism.
• Enzymatic Targeting: The Cytochrome P450 enzyme 1B1 (CYP1B1) is highly overexpressed and specifically localised in DNA-damaged/aberrant cells.
• Activation: Salvestrols act as a substrate for the CYP1B1 protein within damaged cells. The resulting metabolised by-products drive cell regulation and apoptosis.

Scientific Discovery

Identified over a 20-year period of university research, the initial discovery centred on CYP1B1 being highly overexpressed in tumour cells. Since 1997, peer-reviewed studies involving over 3,300 samples (including 2,500 abnormal growths) have confirmed that CYP1B1 is active in abnormal cells while remaining absent in normal functioning cells.

Back to Contents

The NESEM® Advantage

Naturally Pure Products has trademarked NESEMs® (Naturally Elicited Specifically Extracted Molecules). This advanced technology triggers the plant’s natural defence mechanism to extract specific secondary metabolites.

• Pure Extraction: Utilising supercritical fluid extraction with CO2 avoids chemical solvents.
• Clinical Support: Supports regulatory systems via anti-cancer, neurogenesis, and anti-inflammatory activities.

Back to Contents

Ingredients

A blend of key NESEM extracts from:

• Citrus Bioflavonoids (Citrus sinensis): 300mg
• Grape Seed (Vitis vinifera): 75mg
• Pumpkin (Cucurbita maxima): 75mg
• Bulking Agent: Rice flour: 50mg

Product Strength: One capsule = 2,000 Salvestrol points.

Back to Contents

Dosing Guide & Protocols

The Split Dosing Method

To maintain the maximum therapeutic window, split dosing is recommended. This maintains higher concentrations for longer periods by adding a second dose just as the first peaks.

Clinical Protocol: The German Approach to Resistance

A number of physicians in Germany take the following approach: If the patient is not showing any response or is responding very slowly three weeks after they should have reached a steady state (typically 7–9 weeks after treatment has commenced), the dose should be doubled.

The theory is that if there is competitive inhibition for the CYP1B1 binding site from other compounds, an increase in the relative concentration of Salvestrols ensures more compounds are available for metabolism within the target cells.

Back to Contents

Optimising Effectiveness

Key Nutrient Support (Cofactors)

1. Vitamin C (500mg–1000mg): An electron donor that supports/optimises activity.
2. B Vitamins: Specifically Biotin (H), which stimulates CYP1B1 expression, along with B2, B3, and B12.
3. Magnesium: Inadequate levels can reduce CYP1B1 activity by 50%.
4. Iron: CYP1B1 utilises iron at its core to oxidise substrates.
5. EFAs (Omega-3 & 6): Assists membrane transport, especially in centrally involved cases.

Lifestyle & Oxygenation Protocol

Back to Contents

Frequently Asked Questions (FAQs)

1. How long should my patient stay on Salvestrols?

Continued use of a maintenance dose with dietary modifications is recommended for long-term health in remission.

2. What type of diet will support optimisation of Salvestrols?

An organic, whole-food diet is essential. Organically grown produce supplies additional Salvestrol compounds whilst minimising agrochemical inhibitors that block the CYP1B1 enzyme.

3. What affects the function of the CYP1B1 enzyme?

It can be inhibited by environmental toxins (smoking, fungicides, agrochemicals) and certain foods/herbs (grapefruit, high-dose Resveratrol, St. John’s Wort, cannabis, and artificial sweeteners).

4. My patient is taking CBD oil, can they still take Salvestrols?

Yes, but take Salvestrols in the morning and CBD in the afternoon to reduce competitive inhibition.

5. My patient is taking Medicinal Mushrooms, can they still take Salvestrols?

Yes, take Salvestrols in the morning and mushrooms in the afternoon.

6. What lifestyle changes will support optimisation?

Modest exercise, breathing exercises, or oxygen supplementation undertaken 3–4 hours after dosing improves metabolism, as oxygen supplies electrons to the CYP enzymes.

7. My patient has skin lesions/fungal infection, will Salvestrols have any effect?

Yes. Salvestrols modulate topical lesions. We recommend using LypoSalve topically in conjunction with oral Salvestrols for greater effect.

8. My patient is discouraged by slow results, should they stay on them?

“No change” is often a positive result in terminal cases; stability should be viewed as progress. Shrinkage or stability is often only confirmed via MRI/CT scans after several months of steady-state levels.

Back to Contents

Full Clinical References

1. Murray, G.I., et al. (1997). Tumour-specific expression of cytochrome P450 CYP1B1. Cancer Res. 57: 3026-3031.
2. McFadyen, M.C., et al. (1999). Immunohistochemical localisation of CYP1B1 in breast cancer. J Histochem Cytochem. 47: 1457-1464.
3. Murray, G.I., et al. (2001). Regulation, function and tissue-specific expression of CYP1B1. Ann Rev Pharmacol Toxicol. 41: 297-316.
4. Stanley, L.A., et al. (2001). Cytochrome P450 CYP1B1 in early stages of colon tumour development. Drug Metabol Rev. 33: 77.
5. Carnell, D., et al. (2004). Target validation of CYP1B1 in prostate carcinoma. Int J Radiat Oncol Biol Phys. 58: 500-509.
6. Barnett, J.A., et al. (2007). Cytochrome P450 1B1 expression in glial cell tumours. Clin Cancer Res. 13: 3559-3567.
7. McFadyen, M.C.E., et al. (2001). CYP1B1 over-expression in primary and metastatic ovarian cancer. Br. J. Cancer. 85: 242-246.
8. Tsuchiya, Y., et al. (2006). MicroRNA regulates the expression of human CYP1B1. Cancer Res. 66: 9090-9098.
9. Hoang, T.T.V., et al. (2001). CYP1B1 expression in human cervical intraepithelial neoplasia. Br J Cancer. 85: 78.
10. Chang, H., et al. (2005). CYP1B1 and b-catenin for early diagnosis of colorectal cancer. Cancer Detect Prevent. 29: 562–569.
11. Su, J., et al. (2009). Overexpression of CYP1B1 in advanced non-small cell lung cancer. Anticancer Res. 29: 509-515.
12. Tokizane, T., et al. (2005). CYP1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res. 11: 5793-5801.
13. Haas, S., et al. (2006). Expression of xenobiotic and steroid hormone metabolising enzymes in human breast carcinomas. Int J Cancer. 119: 1785-1791.
14. Gibson, P., et al. (2003). CYP1B1 is overexpressed in human colon adenosarcomas. Mol Cancer Ther. 2: 527-534.
15. Ragavan, N., et al. (2004). CYP1B1 expression in prostate zones. Cancer Lett. 215: 69-78.
16. Maecker, B., et al. (2003). Shared tumour-associated antigen CYP1B1 recognised by cytotoxic T cells. Blood. 102: 3287-3294.
17. Chang, J.T., et al. (2007). Aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation. Clin Cancer Res. 13: 38-45.
18. McFadyen, M.C., et al. (1999). Cytochrome P450 CYP 1B1 mRNA in normal human brain. J Clin Pathol. 52: 164.
19. Oyama, T., et al. (2005). Immunohistochemical evaluation of CYP and P53 in breast cancer. Front Biosci. 10: 1156-1161.
20. Vinothini, G., et al. (2008). Immunohistochemical analysis of biomarkers in adenocarcinoma of the breast. Arch Med Sci. 4: 129–139.
21. Kumarakulasingham, M., et al. (2005). CYP profile of colorectal cancer: markers of prognosis. Clin Cancer Res. 11: 3758-3765.
22. Greer, M.L., et al. (2004). CYP1B1 expressed during malignant progression of HNSCC. Proc Am Cancer Res. 45: #3701.
23. McFadyen, M.C., et al. (2004). Cytochrome P450 CYP1B1 activity in renal cell carcinoma. Br J Cancer. 91: 966-971.
24. Furukawa, M., et al. (2004). CYP gene expression levels in peripheral blood mononuclear cells. Cancer Sci. 95: 520-529.
25. Edwards, R.J., et al. (1998). Panel of antibodies against xenobiotic metabolising CYP in humans. Biochem Pharmacol. 56: 377–387.
26. Chang, T.K.H., et al. (2003). PCR analysis of CYP1B1 gene expression in human liver. Toxicol Sci. 71: 11-19.
27. Lin, P., et al. (2003). Association of aryl hydrocarbon receptor and CYP1B1 in lung cancers. Lung Cancer. 42: 255-261.
28. Maecker, B., et al. (2005). Immune responses to hTERT and CYP1B1 in multiple myeloma. Clin Exptl Immunol. 141: 558-562.
29. Dhaini, H., et al. (2003). CYP3A4/5 expression as a biomarker in osteosarcoma. J Clin Oncology. 21: 2481-2485.
30. Downie, D., et al. (2005). Profiling CYP expression in ovarian cancer. Clin Cancer Res. 11: 7369-7375.
31. Bandiera, S., et al. (2005). Proteosomal degradation of human CYP1B1. Mol Pharmacol. 67: 435-443.

Back to Contents